Expression of Organic Cation Transporter SLC22A16 in Human Epithelial Ovarian Cancer
Authors:
- Kiyoshi ItoKIKiyoshi Ito
- Jun-Ichi AkahiraJAJun-Ichi Akahira
- Naoko SatoNSNaoko Sato
- Tohru OnogawaTOTohru Onogawa
- Takuya MoriyaTMTakuya Moriya
- Michiaki UnnoMUMichiaki Unno
- Takaaki AbeTATakaaki Abe
- Hitoshi NiikuraHNHitoshi Niikura
- Tadao TakanoTTTadao Takano
- Nobuo YaegashiNYNobuo Yaegashi
- 1 July 2007
- journal article
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 26 (3) , 334-340
Abstract
The SLC22A16 is one of the newly isolated organic cation transporters, which is responsible for uptake and transport of adriamycin into cells. Adriamycin is considered to be an active agent for ovarian cancer. Recently, the benefit of adding adriamycin to the current standard regimen, paclitaxel and platinum, is evaluated to improve the outcome of patients with ovarian cancer. Therefore, we examined the expression of SLC22A16 in ovarian cancers. Twelve ovarian carcinoma cell lines were used for immunoblotting and reverse transcription-polymerase chain reaction to confirm the expression of SLC22A16 mRNA and protein. Five normal ovaries, 12 ovarian adenomas, and 94 ovarian cancer cases were obtained from patients after surgical therapy. The specimens were used for immunohistochemistry. The median value of relative SLC22A16 gene expression in cell lines derived from clear-cell adenocarcinoma was significantly higher than that in cell lines from other histologies (P < 0.001). Expression of SLC22A16 protein was also detected in cell lines derived from clear-cell adenocarcinoma. The SLC22A16 immunoreactivity was detected in 15 (16%) of 94 epithelial ovarian cancer, 1 (8.3%) of 12 benign adenomas, but 0 (0%) of 5 normal ovary cases. In ovarian cancer tissues, SLC22A16 immunoreactivity wasdetected in 2 (5%) of 38 serous adenocarcinoma, 1 (6.7%) of 15 endometrioid adenocarcinoma, 0 (0%) of 14 mucinous adenocarcinoma, and 12 (46.2%) of 26 clear-cell adenocarcinoma (P < 0.0001, clear-cell vs other histologies). In conclusion, SLC22A16 was abundantly expressed in clear-cell adenocarcinoma. Our results suggest that adriamycin-related chemicals that are taken up via SLC22A16 may have the potential to be effective against clear-cell adenocarcinoma.Keywords
This publication has 27 references indexed in Scilit:
- Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trialInternational Journal of Gynecological Cancer, 2006
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003
- Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinomaAnnals of Oncology, 2003
- Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian CancerJournal of Clinical Oncology, 2002
- Prognostic Factors of Stage IV Epithelial Ovarian Cancer: A Multicenter Retrospective StudyGynecologic Oncology, 2001
- Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.Journal of Clinical Oncology, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Impact of doxorubicin on survival in advanced ovarian cancer.Journal of Clinical Oncology, 1995
- National survey of ovarian carcinoma VI: Critical assessment of Current International Federation of Gynecology and Obstetrics Staging SystemCancer, 1993
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991